Skip to main content
. 2022 Aug 31;13:900963. doi: 10.3389/fimmu.2022.900963

Figure 3.

Figure 3

EVs-DexP inhibits lymphocytes activation in vitro. (A) Flow cytometry analysis of CD4+CD69+ population after the DexP or EVs-DexP treatment of PPs lymphocytes activated by ConA. From left to right, living cells, CD3+ cells, CD4+CD69+cells are detected. (B) CCK-8 assay showing the effect of EVs, DexP and EVs-DexP on PPs lymphocyte proliferation after co-culture for 24h. Data are presented as mean ± SD, * p<0.05 vs. ConA+EVs, *** p<0.001 vs. ConA+EVs, # p<0.05 vs. ConA+DexP; one-way ANOVA.